000270185 001__ 270185
000270185 005__ 20250522160546.0
000270185 0247_ $$2doi$$a10.1101/2021.09.02.21263019
000270185 0247_ $$2altmetric$$aaltmetric:112945343
000270185 037__ $$aDZNE-2024-00756
000270185 1001_ $$0P:(DE-2719)2812578$$aAziz, N. Ahmad$$b0$$eFirst author
000270185 245__ $$aThe association between SARS-CoV-2 infection and neuronal damage: A population-based nested case-control study
000270185 260__ $$c2021
000270185 3367_ $$0PUB:(DE-HGF)25$$2PUB:(DE-HGF)$$aPreprint$$bpreprint$$mpreprint$$s1747922727_14718
000270185 3367_ $$2ORCID$$aWORKING_PAPER
000270185 3367_ $$028$$2EndNote$$aElectronic Article
000270185 3367_ $$2DRIVER$$apreprint
000270185 3367_ $$2BibTeX$$aARTICLE
000270185 3367_ $$2DataCite$$aOutput Types/Working Paper
000270185 520__ $$aObjective: To assess whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with changes in plasma levels of neurofilament light chain (NfL), an extremely sensitive marker of neuroaxonal damage, in community-dwelling individuals.Setting: This study was embedded within the Rhineland Study, an ongoing community-based cohort study in Bonn, GermanyDesign: Cross-sectional nested case-control study.Participants: Participants were selected based on results from a previously conducted seroprevalence survey within the framework of the Rhineland Study. Cases were defined as those individuals who had had two positive confirmatory test results, including a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (N=21). As controls, a random sample of individuals with a negative ELISA test result (Controls I, N=1117), and those with a borderline or positive ELISA test result who failed confirmatory testing (Controls II, N=68), were selected.Outcome measures: Plasma levels of NfL at the time of measurement, as well as change in plasma NfL levels compared to previously measured pre-pandemic levelsResults: After adjustment for age, sex and batch effects, serologically confirmed SARS-CoV-2 infection was neither associated with cross-sectional NfL levels, nor with the magnitude of change from pre-pandemic levels, compared to either of the two control groups. Similarly, after adjustment for age, sex and batch effects, self-reported neurological symptoms – including altered sense of smell or taste, headache, myalgia and fever – were not associated with changes in NfL levels in participants with a serologically confirmed SARS-CoV-2 infection (all p ≥ 0.56).Conclusions: Our findings indicate that mild-to-moderate coronavirus disease-19 is unlikely to be associated with a clinically relevant degree of neuroaxonal damage, even in those cases associated with neurological symptoms.
000270185 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000270185 588__ $$aDataset connected to CrossRef
000270185 693__ $$0EXP:(DE-2719)Rhineland Study-20190321$$5EXP:(DE-2719)Rhineland Study-20190321$$eRhineland Study / Bonn$$x0
000270185 7001_ $$0P:(DE-2719)9000737$$aSantos, Marina$$b1
000270185 7001_ $$0P:(DE-2719)2810403$$aBreteler, Monique$$b2$$eLast author
000270185 773__ $$a10.1101/2021.09.02.21263019
000270185 8564_ $$uhttps://pub.dzne.de/record/270185/files/DZNE-2024-00756_Restricted.pdf
000270185 8564_ $$uhttps://pub.dzne.de/record/270185/files/DZNE-2024-00756_Restricted.pdf?subformat=pdfa$$xpdfa
000270185 909CO $$ooai:pub.dzne.de:270185$$pVDB
000270185 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812578$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000270185 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000737$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000270185 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810403$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000270185 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000270185 9201_ $$0I:(DE-2719)5000071$$kAG Aziz$$lPopulation & Clinical Neuroepidemiology$$x0
000270185 9201_ $$0I:(DE-2719)1012001$$kAG Breteler$$lPopulation Health Sciences$$x1
000270185 980__ $$apreprint
000270185 980__ $$aVDB
000270185 980__ $$aI:(DE-2719)5000071
000270185 980__ $$aI:(DE-2719)1012001
000270185 980__ $$aUNRESTRICTED